BPC-157

What it is

BPC-157, or Body Protection Compound 157, is a synthetic pentadecapeptide composed of 15 amino acids. We first discovered this sequence within human gastric juice, where it serves as a naturally occurring protective agent for the digestive lining. While it was originally isolated from the stomach, the synthetic version used in research is designed to mimic these protective qualities throughout the body.

Researchers became interested in BPC-157 because of its extreme stability. Unlike many other peptides that break down quickly when exposed to stomach acid, BPC-157 remains intact. This resilience led scientists to investigate whether its regenerative properties could extend beyond the gut to influence other tissues like tendons, ligaments, and even the nervous system.

What it does

BPC-157 is primarily studied for its role in "angiogenesis"—the process of forming new blood vessels. By increasing the expression of growth factors like VEGF (Vascular Endothelial Growth Factor), it helps bring nutrients and oxygen to damaged tissues that typically have poor blood flow, such as tendons and ligaments. We see this often in research models where the peptide appears to "bridge" gaps in injured tissue.

Beyond structural repair, users often pursue it for its interaction with the nitric oxide (NO) system, which helps regulate blood flow and inflammation. Research has also investigated its potential to balance neurotransmitters in the brain and protect the gut lining from damage caused by NSAIDs (like ibuprofen). In the wellness community, it is frequently explored by those looking to support recovery from stubborn soft-tissue injuries or chronic digestive issues.

What the evidence says

While the anecdotal reports from the athletic community are numerous, the clinical landscape is still developing. Most of the robust data we have comes from animal models—specifically rats and dogs—where BPC-157 has shown remarkable success in healing Achilles tendons, bone fractures, and intestinal damage. These animal studies suggest a high degree of "pleiotropic" (multi-system) benefits with very low toxicity.

Human evidence remains limited. While some small-scale pilot studies and clinical observations exist, we lack large-scale, double-blind, placebo-controlled human trials to confirm these effects or establish long-term safety. It is important to note that the World Anti-Doping Agency (WADA) added BPC-157 to the prohibited list for athletes in 2022.

What it costs

In the US market, BPC-157 is primarily sold through research chemical suppliers. A typical 5mg vial generally ranges from $45 to $75. For a month of research-based observation, users typically find themselves spending between $100 and $250, depending on the frequency and concentration used in their specific protocols.

Side effects and risks

Research indicates that BPC-157 is generally well-tolerated in animal subjects, but human users sometimes report mild nausea, headaches, or dizziness. Because it promotes blood vessel growth, there is a theoretical concern regarding its use in the presence of active malignancies, as angiogenesis can inadvertently support tumor growth.

As of April 2026, the FDA recently removed BPC-157 from the Category 2 bulk substances list and scheduled it for Pharmacy Compounding Advisory Committee (PCAC) review on July 23–24, 2026, for possible inclusion on the 503A bulks list. Compounding remains restricted in the meantime. We always emphasize that using unapproved research chemicals carries inherent risks regarding purity and long-term health.

Where users source it

Most users obtain BPC-157 from specialized peptide research companies. Because these products are not regulated for human consumption, the quality varies wildly. We recommend looking for suppliers that provide independent, third-party Certificates of Analysis (COAs) for every batch, confirming that the product is at least 98% pure and free from heavy metals or bacterial endotoxins.

Sources

• Sikiric P, et al. (2020). "Stable Gastric Pentadecapeptide BPC 157, Pharmacotherapy, and Surgery." Frontiers in Pharmacology. PMID 32116674
• Chang CH, et al. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing." Journal of Applied Physiology. PMID 21030672
• FDA. (2026). Update on Bulk Drug Substances Reevaluation, April 2026.
• Reuters. (April 2026). "US FDA to convene expert panel to decide broader access to some peptides."
• WADA. (2024). "The Prohibited List."